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Abstract 
Downstream processing aspects of a stable form of amorphous itraconazole exhibiting 
enhanced dissolution properties were studied. Preparation of this ternary amorphous solid 
dispersion by either spray drying or hot melt extrusion led to significantly different powder 
processing properties. Particle size and morphology was analysed using scanning electron 
microscopy. Flow, compression, blending and dissolution were studied using rheometry, 
compaction simulation and a dissolution kit. The spray dried material exhibited poorer flow 
and reduced sensitivity to aeration relative to the milled extrudate. Good agreement was 
observed between differing forms of flow measurement, such as Flow Function, Relative 
flow function, Flow rate index, Aeration rate, the Hausner ratio and the Carr index. The 
stability index indicated that both powders were stable with respect to agglomeration, de-
agglomeration and attrition. Tabletability and compressibility studies showed that spray dried 
material could be compressed into stronger compacts than extruded material. Blending of the 
powders with low moisture, freely-flowing excipients was shown to influence both flow and 
compression. Porosity studies revealed that blending could influence the mechanism of 
densification in extrudate and blended extrudate formulations. Following blending, the 
powders were compressed into four 500 mg tablets, each containing a 100 mg dose of 
amorphous itraconazole. Dissolution studies revealed that the spray dried material released 
drug faster and more completely and that blending excipients could further influence the 
dissolution rate. 
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1. Introduction 
Amorphous solid dispersions (ASD) have received a surge in research interest over 
recent decades, due to the large and increasing number of poorly soluble drugs on today’s 
market(Brouwers et al., 2009; Leuner and Dressman, 2000). Although several examples of 
commercial ASDs exist(Huang and Williams  III, 2017), the technology has sometimes 
lost out to other bioavailability enhancement strategies, often due to problems with 
recrystallisation or perceived difficulties in downstream processing. Although publications 
addressing recrystallisation issues are manifold, far less research has been reported 
addressing the issues of flow and compression(Demuth et al., 2015). 
Efficiency of flow and compression can affect processing times and tablet quality. 
Bridging, arching or rat-holing for instance, can lead to increased processing times, 
inaccurate die fill and unacceptable dose variation. Compression issues can cause sticking, 
picking or flaking of tablets and ultimately reduction in patient compliance(Jain, 1999; 
Leuenberger and Rohera, 1986; Patel et al., 2006). In an age of greater focus on quality by 
design (QbD), global manufacturing competition and ‘right first time’ demands, the need 
to resolve or minimise such issues at the research stage is stronger than ever.  
The purpose of this study was to assess the impacts of spray drying (SD) and hot melt 
extrusion (HME) on the flow, compression and dissolution characteristics of an ASD 
containing itraconazole (ITZ). Comparisons between properties of amorphous dispersions 
prepared by SD and HME are popular,(Davis and Walker, 2018) although most of these 
do not specifically deal with downstream processing issues. We have recently reported the 
preparation of a novel ternary ASD using both SD(Davis et al., 2017) and HME(Albadarin 
et al., 2017). Ternary dispersions have become increasingly popular(Davis and Walker, 
2018) in the struggle to meet the sometimes competing demands of ASDs: increased 
bioavailability, adequate stability, efficient processing, the use of existing plant equipment 
and bearable costs. The formulations, containing drug and excipient polymers Soluplus® 
and HPMCP, displayed excellent stability and enhanced dissolution in both 
studies(Albadarin et al., 2017; Davis et al., 2017). The following is an account of the 
impact of preparation on the downstream processing of one of those formulations. 
2. Materials and Methods 
2.1 Materials 
ITZ (>99%) was purchased from Xi'an Lyphar Biotech Ltd. Accurate analytical standard 
of itraconazole (99.8%) for HPLC calibration was purchased from Sigma Aldrich. Polymers 
Soluplus® & HPMCP HP-55 (HPMCP) were donated by BASF and Shin Etsu respectively. 
Excipients Avicel 101 & Avicel PH 200 LM were donated by FMC and Mannogem granular 
was donated by SPI Pharma. Solvents and chemicals were purchased from Sigma-Aldrich 
and were of HPLC and reagent grade. 
2.2 Spray drying 
Spray drying was conducted using a Büchi B-290 mini spray dryer connected to a B-295 
inert loop. A 2-fluid pneumatic nozzle (0.7 mm) was fitted and liquid feedstock was pumped 
at 4 mL/min (15%). Drying nitrogen was set at maximum by fixing the aspirator at 100% 
(35 m3/h). A solution of ITZ-Soluplus®-HPMCP (30-40-30 w/w) in dichloromethane-
methanol 7-10 (v/v) (1.0 L, 10.0 % w/v) was pumped through the nozzle at inlet temperature 
100 oC, producing an outlet temperature of 65 ± 2 oC. High yields (88.6%) were achieved by 
using high spray gas rates (670 L/h) and attaching the high efficiency cyclone option. 
Powdered product was immediately transferred into a stainless steel pan and dried overnight 
in a vacuum oven at 40 oC and 10-2 mBar to ensure complete removal of residual levels of 
solvent. Powder was then stored in a sealed glass bottle in a desiccator over anhydrous 
molecular sieves. 
2.3 Hot melt extrusion and milling 
Itraconazole, Soluplus® and HPMCP 30:40:30 (w/w) (50g) were pre-mixed by hand in a 
polythene bag, having first removed larger particles of HPMCP, by passing through a 435 µm 
sieve. The pre-mixed powders were then manually fed into a Three-Tec twin-screw extruder 
(Three-Tec GmbH, Germany) with a barrel diameter of 12 mm and an L/D ratio of 40:1. The 
set points of the six heating zones, from feed to die, were 80, 110, 120, 140, 150 and 150 °C, 
respectively and screw speed was maintained at 15 rpm throughout. Following extrusion the 
material was milled for 1 min at 20 Hz using a 25 mL stainless steel jar attached to a Retsch 
Mixer Mill MM 400 ball mill (Retsch GmbH, Germany). Milled extrudate was sieved 
through 435 and 90 µm sieves and the 90 – 435 µm and < 90 µm fractions were stored 
separately in sealed glass bottles in a desiccator over anhydrous molecular sieves. 
2.4 Scanning electron microscopy (SEM) 
Drug polymer formulations were attached to double sided carbon tape and sputter coated 
with a thin layer of gold followed by imaging using a Joel CarryScope JCM-5700 scanning 
electron microscope. Micrographs were recorded at various magnifications, using a beam 
acceleration voltage of 5 kV, a spot size of 40 and a working distance of 12. 
2.5 Powder Rheometry 
Powder flow was analysed using an Freeman FT4 powder rheometer in a manner  
previously reported(Freeman, 2007). Stability and Variable flow rate was performed in the 
25 mm vessel, Aeration in the 25 mm vessel and Shear in the 10 mL and 1 mL vessels. 
2.6 Compaction simulation 
Powders were tableted using a Gamlen R-series tablet press containing a 500 kg load cell 
and 6 mm punch and die. The material was subjected to uniaxial compression tests to form 
flat-face cylindrical tablets with a target weight of 90 mg. Punch load and displacement were 
measured during compression and the effect of compaction forces from 0.5 to 5 kN, 
equivalent to pressures of 17 to 173 MPa, was studied. Tablet hardness, defined as the 
diametral force required to break the compact, was investigated using a PharmaTest hardness 
tester (Pharma Test Apparatebau AG, Germany) immediately after tabletting. 
2.7 True density 
The true density of the extruded and spray dried products and powder blends was 
measured under ambient conditions using an helium pycnometer (AccuPyc II 1340, 
Micromeritics Inc., Norcross, GA). The volume of the pycnometer was verified with a 
standard before carrying out analysis. During sample analysis five purge cycles were 
recorded for samples and the reported result is an average of measurements made on three 
different days. 
2.8 Formulation and tabletting 
ASD products and excipients were accurately weighed as described in Table 4 and the 
individual components were vortex mixed for 2 min in 10 mL vessels. The resultant 
prototype tablet formulations were pressed according to scalable parameters determined 
through small scale compaction simulation performed on 90 mg material. Blends were 
weighed into a 0.5 inch (12.7mm) diameter die and then pressed at 1000 kg pressure on a 
manual hydraulic tablet press to form flat-face cylindrical tablets with a target weight of 
500 mg. 
2.9 In-Vitro Dissolution Studies 
Drug release studies were carried out using non-sink conditions, in a USP type II 
apparatus, PharmaTest dissolution tester (Pharma Test Apparatebau AG, Germany), with 900 
mL 0.1 N HCl buffer (pH 1.2) per well, a paddle speed of 100 rpm and a temperature of 37 ± 
0.2 °C. Formulated tablets of mass 500 mg, equivalent to 100 mg of drug were added to the 
dissolution vessel (n = 3), with start times staggered by 2 min. 5 mL aliquots of media were 
withdrawn at predetermined intervals (0.25, 0.5, 0.75, 1, 2, 3, 4, and 6 h), filtered through a 
0.45 μm polytetrafluoroethylene (PTFE) syringe filter and then the first 1 mL of filtrate was 
discarded. 500 µL of the filtrate was subsequently added to 500 µL of HPLC mobile phase in 
2 mL HPLC vials. 5 mL of fresh medium was immediately replaced following each 
withdrawal. 
2.10 High performance liquid chromatography (HPLC) 
Dissolution samples were analysed using an Agilent (Agilent, Little Island, Cork) 1260 
Infinity II high performance liquid chromatography system, comprising of quaternary pump 
G1311B and diode array detector G1315D set at wavelength 263 nm. The thermostated 
column compartment G1316A was set at 25.0 oC and equipped with a Kromasil 100 C18 
5 µm 250 x 4.6 mm (Kromasil, Mainz, Germany) RP-HPLC column. The system was 
operated under isocratic flow at 1 mL/min using, a mobile phase of 
acetonitrile:water:diethanolamine (69.95/30/0.05, v/v/v). Samples were injected from 
autosampler G1329B in volumes of 20 µL and data was collected and analysed by Agilent 
OpenLAB CDS Chemstation software. Standards of ITZ (99.8% purity) were prepared from 
a stock solution of 1 mg/mL in methanol, to quantify the levels of drug in the dissolution 
media. 
3. Results and Discussion 
3.1 Preparation of Amorphous Solid Dispersions by Spray Drying and Hot Melt Extrusion 
In our previous studies we discovered that it was possible to prepare novel ternary 
amorphous dispersions of BCS class II drug itraconazole by hot melt extrusion(Albadarin et 
al., 2017) and by spray drying(Davis et al., 2017). Following rational polymer 
selection(Davis et al., 2015), these blends proved to have excellent stability and enhanced 
dissolution profiles. As design of experiments (DoE) had previously been performed during 
formulation design, only one blend was selected for downstream processing. A ternary ratio 
of itraconazole-Soluplus®-HPMCP 30-40-30 (w/w) was selected to test a high drug load and 
simultaneously facilitate HME processing, by choosing a Soluplus® ratio that was slightly 
higher than that of HPMCP. 
Particle size is a critical factor in powder flow. Often the particles from spray drying 
processes are very small (< 10 µm)(Vehring, 2008), which can be excellent for dissolution, 
but challenging for powder flow. It is possible to increase particle size by changing nozzle 
type to a pressure nozzle(Beyerinck et al., 2010), processing parameters, drier geometry or 
feed stock concentration. Of these options, the most directly available was an increase in 
feedstock concentration, although it is likely that a pressure nozzle would be more effective. 
More concentrated feed solutions produce more viscous droplets and hence larger 
particles(Vehring, 2008). For this reason the feed was prepared at 10% (w/v), following 
optimisation experiments on the dichloromethane-methanol solvent system(Davis et al., 
2017), leading to an optimal ratio of 7-10 (v/v). In addition, the yield of the spray dried 
powder was optimised by tuning processing parameters. In particular, when the spray gas rate 
was increased from 25 mm (301 L.h-1) to 55 mm (670 L.h-1) on the flow meter, the yield 
increased from 51% to 89%. 
With hot melt extrusion, it was less difficult to prepare the quantities of material required 
(at least 100 g), as the materials are not diluted in liquid before feeding to the equipment. 
However, it was found that sieving, pre-mixing and manually feeding the ternary materials 
was favourable, to promote adequate mixing and prevent system overload by excess torque. 
Early runs lead to the production of opaque amber material and excessive torque. The torque 
issue was ameliorated by modifying the ternary blend mixture from itraconazole-Soluplus®-
HPMCP 30-35-35 to 30-40-30 (w/w), as the HPMCP was difficult to extrude, but the 
Soluplus® processed very well. In addition, the adjustment of zone temperatures by 
increasing zones 4 and 5 from 130 oC and 140 oC to 140 oC and 150 oC respectively, resulted 
in production of glassy yellow material. After cooling, the glassy extrudate was milled, 
sieved and stored. 
Cleaning of the extruder was also challenging, requiring addition of pure Soluplus® as a 
‘cleaning polymer’, followed by hot removal of thermocouples, hot removal of barrels from 
screws, cooling, separation of barrel blocks using levers and finally immersion in warm 1% 
surfactant with sonication. 
3.2 Particle size and morphology 
The impact of particle size and morphology on powder flow is well known and can 
drastically effect the efficiency of pharmaceutical powder processes, such as die filling(Gallo 
et al., 2011; Hancock et al., 2002; Nokhodchi et al., 2007; Sinka et al., 2004; Sivasankaran et 
al., 2010; Wu and Cocks, 2004; Xie and Puri, 2006). Variation in powder composition or 
flow can lead to unacceptable deviations in tablet weight and content uniformity, possibly 
leading to the rejection of a batch in extreme circumstances. Poor flow can potentially also 
lead to inefficient or even dangerous processes on the plant, caused by bridging or caking of 
powder masses during storage in containers or silos and the potential for powder flooding. 
Because spray dried powder contains particles mostly < 10 µm and milled extrudate < 90 µm 
(or 90 – 435 µm, for the larger sieved extrudate fraction), the cohesion and flow of these 
powders will differ profoundly and require differing hopper angles, orifices or alternative 
storage design for safe and efficient handling. 
Scanning electron microscopy (SEM) was performed on the materials to provide insight 
into particle size and morphology. Itraconazole was received as relatively flat, wedge-like 
crystals (Figure 1a) approximating 40 µm length by 10 µm width, with a mostly smooth 
surface that nevertheless displayed several brittle shards. Soluplus® was received as much 
larger, approximately spherical granules (Fig 1b) with a diameter approximating 250 µm. 
HPMCP (Fig 1c) was received as pod- or cocoon-like elongated particles approximating 350 
µm by 70 µm, with a smooth but broken surface. The physical mix was a combination of the 
above, although the difference in size and shape between the small itraconazole particles and 
the large HPMCP particles was particularly apparent (Fig 1d). This shaped the decision to 
sieve the HPMCP before powder blending and extrusion. 
The extruded particles were ball milled and sieved prior to SEM analysis. The particles 
appeared as irregularly shaped granules, comprising considerably more material per granule 
than the spray dried particles. There were many rough spots on the surface of each individual 
granule, representing possible areas for particle interlocking and cohesion. Particles were 
typically 50 µm x 55 µm in the < 90 µm sieved fraction (Fig 1e) and 240 µm x 350 µm in the 
90 - 435 µm sieved fraction (Fig 1f). The spray dried sample appeared as a combination of 
some hollow spheres with diameters of up to 30 µm (Fig 1g), some burst hollow spheres (Fig 
1h) of similar diameter, but mostly crumpled spheres of less than 10 µm, that had grouped 
into agglomerates of various shapes, with 40 - 60 µm in total diameter. The particles size of 
the spray dried material in this study represented an increase to that of our previous work, 
where a lower feed concentration of 0.5% (w/v) typically led to particle diameters of 1.5 -
 2.4 µm, depending on formulation(Davis et al., 2017). Although increasing the feed 
concentration did increase the particle size, the spray dried particles were still very small. 
While this is advantageous for dissolution, the powders are expected to be quite cohesive 
during flow analysis. 
3.3 Powder Flow 
3.3.1 Powder stability during flow 
Because unknown powders may be prone to attrition, agglomeration or caking, it is 
important to begin by measuring whether the powder will change during the course of testing. 
To discover if the flow properties alter under the stresses imposed during flow,(Iveson et al., 
2001; Salman et al., 2002) the ‘stability program’ runs the powder through a series of 
identical conditioning and test cycles: if the powder is stable then the results from each 
measurement are similar. This is observed as a straight line from points 1 through to 7 in 
Figure 2. The stability index, defined in equation 1, is the ratio of energy in test 1 to energy in 
test 7: 
 𝑆𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑖𝑛𝑑𝑒𝑥, 𝑆𝐼 = 𝐸𝑛𝑒𝑟𝑔𝑦 𝑇𝑒𝑠𝑡 7 𝐸𝑛𝑒𝑟𝑔𝑦 𝑇𝑒𝑠𝑡 1⁄  (1) 
Generally, a stable powder will have an SI approximating 1, powders with SI > 1 are 
unstable, affected by de-aeration, agglomeration, segregation, moisture uptake or electrostatic 
charge and powders with SI < 1 are unstable, affected by attrition, de-agglomeration, over-
blending or coating of the vessel and blade by an additive(Freeman, 2007). The data in 
Figures 2 and 3 demonstrated that milled extrudate (HME & BM), physical mixture, 
itraconazole and spray dried ASD were largely stable to flow rate changes, with SI values of 
0.96 ± 0.06, 1.08 ± 0.11, 0.97 ± 0.18 and 1.24 ± 0.26, respectively. Only excipients Soluplus® 
(1.91 ± 0.35) and HPMCP (1.35 ± 0.17) were unstable with respect to flow stress, with the 
stability results for HPMCP particularly inconsistent (data not shown). The underlying cause 
for the instability may be connected to static charge accumulation in HPMCP during testing. 
3.3.2 Powder variable flow rate during flow 
The rate at which powders are handled and transferred varies and the sensitivity of a 
powder to this is an important factor. Often, cohesive powders are more sensitive to changes 
in flow rate than non-cohesive or granular materials. During the variable flow rate test 
(Figure 2), the flow rate is reduced from 100 mm/s to 10 mm/s over tests 8-11. The flow rate 
index (FRI) is given by equation 2: 
 𝐹𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 𝑖𝑛𝑑𝑒𝑥 (𝐹𝑅𝐼) = 𝐸𝑛𝑒𝑟𝑔𝑦 𝑇𝑒𝑠𝑡 11 𝐸𝑛𝑒𝑟𝑔𝑦 𝑇𝑒𝑠𝑡 8⁄  (2) 
Usually, a high flow rate sensitivity (usually for very cohesive powders) is depicted as 
FRI > 3.0; an average flow rate sensitivity (including most powders) lies between 
3.0 > FRI > 1.5; flow rate insensitive materials (with large PSD or surface coating) have 
FRI ≈ 1.0 and pseudoplastic or Neutonian Flow rates (such as powders containing flow 
enhancers like magnesium stearate) are found with FRI < 1.0(Freeman, 2007). 
As depicted in Figures 2 and 3 the experimental FRI values recorded were as follows: 
itraconazole 1.89 ± 0.03, Soluplus® 1.28 ± 0.06, HPMCP 1.63 ± 0.24, HME/BM 1.40 ± 0.02; 
physical mix 1.68 ± 0.11 & spray dried 3.73 ± 0.35. So, most of the materials can be 
classified as having average flow rate sensitivity, with the Soluplus® and milled extrudate 
edging towards being insensitive. The clear exception was the spray dried material, with a 
high FRI value of 3.73, as would be expected for a cohesive powder comprised of very small 
particles. The difference between the spray dried ASD and the milled extrudate ASD was 
3.73 – 1.40 = 2.33 units. It would therefore be reasonable to expect a significantly different 
sensitivity of these two ASDs to flow rate during processing, despite their identical chemical 
compositions. 
3.3.3 Powder Aeration Studies 
The bulk properties of all powders are to some extent influenced by air because the inter-
particulate spaces themselves contain air. The volume of air impacts interparticular 
interactions and flow. Some powders are readily aerated and require only modest quantities 
of air to transform into a fluidised bed. Others are cohesive and therefore not easily aerated, 
although the flow properties may still improve with increasing air entrainment. The aeration 
ratio (AR) is given by the equation: 
 𝐴𝑒𝑟𝑎𝑡𝑖𝑜𝑛 𝑅𝑎𝑡𝑖𝑜, 𝐴𝑅 = 𝐸𝑛𝑒𝑟𝑔𝑦 (𝐴𝑖𝑟 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 0) 𝐸𝑛𝑒𝑟𝑔𝑦 (𝐴𝑖𝑟 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 10)⁄  (3) 
Powders with AR ≈ 1 are not sensitive to aeration and are generally very cohesive. An 
average sensitivity to aeration with 2 < AR < 20 is found for most powders. Very sensitive 
powders with AR >> 20 will most likely become fluidised easily. Referring to Figure 4, the 
three raw materials and the two ASD powders were measured on the aeration program and 
produced the following AR results: HPMCP = 1.38 – 1.68 (not sensitive, very cohesive); 
Soluplus® = 0.45 – 0.54 (not sensitive, special case); itraconazole = 1.62 – 3.51 (cohesive to 
average); milled extrudate = 45.9 – 58.2 (very sensitive, non-cohesive); spray dried = 1.73 – 
2.02 (not sensitive, very cohesive)(Freeman, 2007).  
These results can be rationalised by considering the particle size and morphology of the 
powders (Figure 1 & section 3.2). HPMCP particles are elongated along one axis and 
typically several hundred µm long, so a preference for horizontal stacking may add to 
cohesion. Soluplus is spherical and around 300 µm in diameter, the spherical shape is quite 
aerodynamic and allows a laminar flow around the spheres, leading to the very low AR value 
of 0.48. This may also explain the unexpected requirement for more energy as the blade 
flows through the sample at higher aeration velocities. Itraconazole comprises straight, flat 
crystalline wedges of approximately 10 µm x 40 µm, so it is unsurprising that this material is 
also cohesive and AR insensitive. The test on the milled extrudate was performed prior to 
sieving. The particles contain a significant fraction of larger particles (> 300 µm), with 
various shapes and sizes, so the material was non-cohesive and very sensitive to aeration. 
Finally, the spray dried material contains hollow, burst and crumpled spheres, with many 
particles < 10 µm. The material is very cohesive due to the tiny particle size and therefore AR 
insensitive 
The average AR values for the milled extruded and spray dried samples were 50.23 ± 6.89 
and 1.88 ± 0.15 respectively, a difference of 48.35 AR units, representing a significant 
difference in sensitivity towards aeration. The result has implications for understanding 
Würster coating and other processes that intentionally use air or for flow by gravity (Bruni et 
al., 2007; Freeman, 2007; Leturia et al., 2014). In particular, die filling during tabletting 
requires both that the powder fill the die by gravity and also that the air in the die exits easily 
through the particles as they ingress(Sinka et al., 2004; Wu and Cocks, 2004). As speed of 
tabletting increases this becomes more important. 
3.3.4 Powder shear testing 
Shear cell testing is perhaps the most studied and understood flow test performed using 
powder rheometry(Fitzpatrick et al., 2004; Jenike, 1964; Schulze et al., 2008; Schwedes, 
2003; Walker, 1966). The procedures and testing sequences have been reported 
elsewhere(Freeman, 2007), but briefly consist of powder conditioning, consolidation, vessel 
splitting, re-consolidation and finally shear testing. The tests were performed in triplicate to 
increase accuracy. FT4 software enabled automatic construction of Mohr circles, providing 
valuable data such as cohesion (C), unconfined yield strength (UYS) , major principle stress 
(MPS), minor consolidation stress (MCS), angle of internal friction (AIF), Peschl’s Relative 
Flow Function (RelP) (Peschl and Colijn, 1977) and Jenike’s Flow function (FF of ffc)(Ennis, 
B J; Witt, W; Weinekoter, R; Sphar, D; Gommeran, E.; Snow, R H; Allen, T; Raymus, GJ; 
Litster, 2007; Freeman, 2007; Jenike, 1964). The equations for FF and RelP are given as 
follows: 
 𝐹𝑙𝑜𝑤 𝐹𝑢𝑛𝑐𝑡𝑖𝑜𝑛, 𝐹𝐹 = 𝑀𝑃𝑆 𝑈𝑌𝑆⁄  (4) 
 RelP = (𝑀𝑃𝑆 − 𝑀𝐶𝑆) 𝑈𝑌𝑆⁄  (5) 
In Figure 5, the yield loci (plot of applied normal stress vs shear stress) of itraconazole, the 
physical mixture and the two ASD powders were plotted with the corresponding shear 
parameters reported in Table 1. The most frequently reported value derived from shear cell 
data to describe flowability is the Jenike Flow Function (FF of ffc)(Freeman, 2007; Jenike, 
1964). The FF values for itraconazole (2.03 ± 0.03) and the spray dried ASD (3.45 ± 0.18) 
indicated that they were cohesive, the physical mixture was very cohesive (1.98 ± 0.25) and 
the milled extruded ASD was free-flowing (57.01 ± 53.62). The low standard deviation 
values indicated that repeatability was excellent for the cohesive powders but rather poor for 
the free-flowing extrudate, demonstrating that this test was more accurate for cohesive 
powders(Freeman, 2007). Similarly (but with subtle differences in cohesive ranking), the 
Relative Flowability (RelP)(Peschl and Colijn, 1977) values indicated that itraconazole and 
the physical mix were extremely cohesive, the spray dried ASD was very cohesive and the 
milled extrudate was cohesionless (Tables 1 & 3). 
The highest values of Unconfined Yield Strength (UYS) were found in the physical 
mixture (11.83 kPa) and itraconazole (10.75 kPa), with much lower values for the spray dried 
(4.14 kPa) and milled extrudate (2.98 kPa) ASDs, respectively. This was expected, as more 
cohesive powders will generally have higher values for UYS(Freeman, 2007). In addition, a 
steeper yield locus often represents a powder that is more sensitive to increasing levels of 
consolidation. The highest AIF value was for the physical mixture (44.09 ± 8.75o), followed 
by itraconazole, roughly equal to the extruded/milled ASD and finally the lowest value was 
for the spray dried ASD (27.75 ± 0.61o). Therefore the pure drug was most sensitive to 
increasing consolidation and the spray dried ASD was least sensitive overall and less 
sensitive than the milled extrudate (by 8.64o on average). Consolidation results have 
implications for packaging, shipping and processing considerations. 
3.3.5 A comparison of powder flow testing parameters 
To better understand the accuracy and precision of the various parameters used to measure 
flow, simple mass/volume measurements were taken to calculate the Hausner ratios and 
Carr’s indices for the powders. Although these parameters have little theoretical basis, they 
are easily obtained and have been used to describe powder flow for many decades, so their 
inclusion seems worthwhile. The FT4 rheometer conditions the powder prior to recording 
bulk density and this imparted a high degree of repeatability (accuracy) on the values 
obtained (Table 2), with standard deviations (n = 3) between 0.01 and 0.08 g/mL for the 5 
powders included. Conversely, the ‘measured’ values were simply taken as a recording of 
pouring the powders from their containers in whatever state they happened to be resting in 
(raw materials were stored in 1 kg bags (HPMCP), 5 kg bottles (Soluplus) and 1 kg bottles 
(itraconazole) and ASDs (100 g) in sealed glass jars in a desiccator) into a pre-weighed 
graduated cylinder then re-weighing to get the density and this was performed once. 
Although the repeatability of bulk density values for Soluplus® and HPMCP from the FT4 
and direct measurements was excellent (± 0.01 g/mL) and those of spray dried and milled 
extrudate were comparable (± 0.05 & 0.10 g/mL respectively), the value for itraconazole 
differed wildly (± 0.19 g/mL, or 37%) (Table 2). The net effect of these differences is 
demonstrated by Carr index values of 43.39 and 10.71 for itraconazole depending on the bulk 
density value taken - this clearly demonstrated the requirement for a more consistent method 
for measuring powder flow, particularly for powders like itraconazole that are both cohesive 
(C = 2.55 ± 0.17 kPa) and sensitive to consolidation (UYS = 10.75 ± 0.56). 
To explore these points further, the various flow parameters obtained from the FT4 
rheometer were tabulated with the Hausner ratio and Carr’s index in Table 3. For 
itraconazole, interpretations of values for the Flow Function, Relative Flowability, Flow rate 
index, Aeration ratio, Hausner ratio and Carr’s index were in good agreement with each 
other: cohesive, extremely cohesive, average flow rate sensitivity, average aeration 
sensitivity, extremely poor flow and extremely poor flow, respectively. Similar agreement 
was observed for Soluplus®, HPMCP, physical mixture, spray dried ASD and the milled 
extrudate. The high level of agreement between results suggests precision in the flow 
parameters from the instrument. In general, the accuracy of the measurements from the FT4 
was excellent. However, while analysing the milled extrudate sample, although the FRI 
measurement was very accurate (SD ± 0.02), the results for RelP and FF were very inaccurate 
(± 40.07 and ± 53.62 respectively), reflecting the lack of sensitivity of shear testing towards 
larger particles. 
3.3.6 The effect of additional excipients on ASD powder flow 
To see if flow could be improved by blending with appropriate excipients, the spray dried 
and the milled extrudate ASDs were blended (separately) with Avicel PH 200 LM (Av200) 
and Mannogem granular (ManG) to give four formulations (Table 4). In order to enhance 
powder flow, these excipients had relatively larger particle sizes (on average 200 µm and 400 
µm, respectively), although the difficulty in homogenously mixing powders of differing sizes 
is well documented. Furthermore, both excipients were specially treated commercial forms of 
MCC and mannitol respectively, both known for their excellent compression characteristics. 
Thirdly, due to the moisture-sensitive nature of amorphous dispersions, both excipients were 
selected for their low moisture (‘LM’) or non-hygroscopic (mannitol) properties. To achieve 
a 100 mg drug dose in the final tablet (the standard itraconazole dosage) required 333.3 mg 
(66.6% w/w) of the ASD, allowing only 150 mg (30% w/w) of excipient for the 500 mg total, 
with disintegrant and lubricant accounting for the remaining 3.4% (w/w). 
In order to analyse the effect of these excipients on powder flow, further shear studies 
were performed using the 1 mL annular shear cell (due to lower powder quantities). The yield 
locus plots are depicted in Figure 7 with shear data in Table 5. Considering the spray dried 
ASD and formulations, addition of Av200 reduced cohesion by 0.46 kPa and increased FF by 
1.01 units. Conversely, addition of ManG increased cohesion by 0.25 kPa and decreased FF 
by 0.25 units. Considering milled extrudate the picture was dissimilar: addition of Av200 
reduced cohesion by 0.24 kPa and increased FF by 3.56 units, but addition of ManG further 
reduced cohesion by 0.46 kPa and further increased FF by 14.18 units. Clearly the 
enhancement or hindrance of flow by addition of further excipients is a combination of many 
complex factors, is specific to the precise set of interparticulate forces acting between the 
given excipient and dispersion and is therefore difficult to predict or simulate. 
3.4 Compression 
3.4.1 Tabletability and Compactability of raw materials and ASDs 
In order to better understand the effects of ASD preparation on tabletability (compaction 
pressure vs tensile strength) and compactability (solid fraction vs tensile strength), the 
materials were examined using a Gamlen tablet press (GTP) and a PharmaTest hardness 
tester. The data was converted into plots according to equation 6: 
 𝜎 = 2𝐹 п𝐷𝐻⁄  (6) 
Where, σ is tensile strength, F is the load required to fracture the tablet, D is the tablet 
diameter and H the tablet height(Banker et al., 2002; Endicott et al., 1961; Fell and Newton, 
1970).  
The spray dried material produced a stronger compact than milled extrudate at similar 
compaction pressures (Figure 6a). This was attributed to the bonding area, i.e. the effective 
surface area taking part in physical interparticulate bonding, which is greater for smaller 
particles (Olsson and Nyström, 2001). Tablet tensile strength is related to both bonding area 
and bonding strength with the overall strength due to an interplay between the two (Osei-
Yeboah et al., 2016; Sun, 2011). Assuming that a minimal amount of brittle fracture occurs in 
the powders during the initial stages of compression, the greater mechanical strength of spray 
dried compacts can be partly attributed to the smaller particle size produced by spray drying 
relative to milled extrudate. 
The strongest compact was formed with pure HPMCP (slightly stronger than pure 
Avicel 101) and the weakest with Soluplus® (Figure 6a). It is also possible that differences in 
excipient hygroscopicity impacted compact strength, by introducing moisture mostly during 
ambient storage or during weighing and compression, causing more hygroscopic materials 
(such as HPMCP) to form stronger compacts(Malaj et al., 2010; Sun, 2011). Confirmation of 
this would require further testing. 
The compactability (tensile strength vs solid fraction) profiles (Figure 6b) showed a range 
in tablet tensile stress with solid fraction. Soluplus® was very compacted at the tensile 
strengths studied, with values over 0.95. Milled extrudate fractions were comparable to 
values obtainable for a typical filler like Avicel 101 (MCC), but spray dried ASD had lower 
solid fraction ranges, up to 0.80. HPMCP had the lowest values, up to 0.68, showing the 
possibility for further compaction at higher pressures. 
3.4.2 Tabletability and Compactability of Prototype Tablet Formulations 
Formulation of spray dried powders with Av200 (Formulation 1) improved tabletability, 
however inclusion of ManG (Formulation 2) produced softer tablets (Figure 8a). Neither 
Av200 nor ManG improved the tabletability of extruded powders, with both Formulation 3 
and Formulation 4 producing softer tablets than the milled extrudate alone. Addition of either 
excipient to the milled extrudate ASD produced a more linear relationship between 
compaction pressure and tensile strength above pressures of 115 MPa, and this was more 
marked with the ManG formulation. 
Compactability values were higher for all extruded material formulations, although 
inclusion of both Av200 and ManG resulted in enhanced compactability values for all of the 
spray dried and extrudate formulations (Figure 8b). 
3.4.3 Compressibility of Prototype Tablet Formulations 
Tensile strength measurement is carried out on the tablet following compression and is an 
out-of-die method, however analysis of the powder in-die during compression provides 
further information, especially on elastic deformation. The non-linear behaviour observed 
between tensile strength and compression pressure of the extruded powder, Formulation-3 
and Formulation-4 provided the opportunity to investigate whether a change in the 
mechanism of densification from plastic to elastic deformation had occurred. Figure 9 
compares the behaviour of extruded powder and extrudate formulations 3 & 4 in-die, 
illustrating both the change in porosity with compression pressure (dotted line) and the 
resulting Heckel plot, based on the logarithmic change in porosity (full line). Porosity was 
calculated by determining the solid fraction using the density of a compact from its mass and 
volume then dividing by the true density (equations 7 and 8). 
 
𝑆𝑜𝑙𝑖𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =  
𝑇𝑎𝑏𝑙𝑒𝑡 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
𝑇𝑟𝑢𝑒 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
=
𝑀𝑎𝑠𝑠/(п ∙ (
𝐷𝑖𝑎𝑚𝑒𝑡𝑒𝑟
2 )
2
∙ 𝑇ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠)
𝑇𝑟𝑢𝑒 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
 
(7) 
 𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 = 1 − 𝑆𝑜𝑙𝑖𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 (8) 
For each of the three Heckel plots, an initial non-linear region was observed, typically 
attributed to particle rearrangement (Heckel, 1961; Shapiro, 1995) or particle 
fragmentation(Duberg and Nyström, 1982). This was followed by a linear region indicating 
plastic deformation(Heckel, 1961), then a further non-linear region signifying elastic 
deformation of the powder bed(Sun and Grant, 2001). While all three regions are present in 
each of the plots, the nature of the regions varied from powder to powder. The extruded 
material (Figure 9a) exhibited a shortened plastic deformation region with elastic deformation 
shown to be the mechanism of compression for pressures greater than 70 MPa. This is in 
agreement with the plateau in the tensile strength observed for these powders at higher 
compression pressures (Figure 8a). Similar behaviour is shown by Formulation-3 (Figure 9b), 
but with a lesser degree of elastic deformation. Formulation-4 (Figure 9c), which maintained 
a linear relationship between tablet tensile strength and compression pressure for the 
pressures studied (Figure 8a), behaved close to linearly, even at the highest pressures. 
Previous studies have shown that while it is difficult to completely separate the contributions 
of plastic and elastic deformation mechanisms to the strength of a compact following 
compression, strength increases are mainly due to the formation of physical bonds between 
particles due to plastic deformation(Hiestand, 1997). Much of the elastic deformation is 
temporary and disperses once the load is released(Picker, 2001) however it seems that in this 
case some tensile strength increase due to elastic deformation is permanent, indicated by the 
fact that the tensile strength of extruded powders in Figure 8 continues to increase at higher 
pressures and does not completely plateau. 
3.5 Dissolution studies 
Dissolution profiles of tablets 1, 2, 3 and 4 are plotted in Figure 10. As expected, the 
formulations containing spray dried dispersions performed better than those containing milled 
extrudate(Albadarin et al., 2017; Davis et al., 2017). Drug concentrations at 2 h approximated 
50 µg.mL-1 and 30 µg.mL-1, respectively. After 6 h, average drug concentrations increased to 
82.3 µg.mL-1 in tablet 1 (spray dried with Av200), 69.1 µg.mL-1 in tablet 2 (spray dried with 
ManG), 44.2 µg.mL-1 in tablet 3 (milled extrudate with Av200) and 44.5 µg.mL-1 in tablet 4 
(milled extrudate with ManG). The highest drug release observed was from one of the spray 
dried and Av200 tablets, achieving a 91.0 µg.mL-1 concentration after 6 h, a drug release of 
81.9%. 
The most immediate factors facilitating the higher performance of the spray dried material 
were the smaller particle size, narrower particle dimensions and larger particle surface area, 
relative to milled extrudate (Figure 1). Only the smaller sieved fraction (< 90 µm) of milled 
extrudate was brought though for dissolution studies, as this was closer in particle size to the 
spray dried formulation and therefore more comparable. For an absolute comparison an 
identical particle size would be best, although this would require a very small sieve fraction 
from the milled extrudate (or use of a jet mill) and a further enhancement of spray dried 
particle size by a factor of 5 to 10. This could be achieved using alternative spray drying 
parameters, such as a pressure nozzle(Beyerinck et al., 2010). 
 Interestingly, the Av200 tablets performed better than the ManG tablets on average, 
however the results were not simplistic and at certain times the performance of ManG tablets 
exceeded Av200 tablets. For example, the Av200 formula out-performed the ManG formula 
during almost all of the milled extrudate tests, apart from the first half hour, where it was 
marginally higher and the final test point (6 h), where it was also marginally higher. 
Additionally, for the spray dried tests, the ManG formula out-performed the Av200 formula 
during the first 2 hours, but this changed between 2 h and 3 h and the Av200 formulation then 
released more drug through to 6 h (Figure 10). Depending on the type of formulation required 
(e.g. immediate or sustained release) either of these results could be seen as a favourable 
direction for development. It is worth noting that although the ASD and ‘filler’ are present in 
each tablet at 66.6% and 30% (w/w) respectively, the impact of ‘filler’ excipient on each 
formulation is significant. For example, the highest recorded drug release (at 6 h) for spray 
dried with avicel was 91.0 µg.mL-1 and the lowest for spray dried with mannogem was 
67.6 µg.mL-1, a difference of 23.5 µg.mL-1. 
Clearly, formulation of either the spray dried or the extruded ASD into an optimised tablet 
is a very complex task and difficult to predict. Firstly, further studies are recommended for 
formulation optimisation, such as examining ASD level, filler type, filler level, lubricant level 
and other factors impacting dissolution rate; including the potential for gelling polymer 
networks (GPN)(Demuth et al., 2015). Secondly, optimisation of tablet processing factors 
such as the effect of compression pressure on dissolution, the presence/absence of crystalline 
drug caused by compression, reduced particle surface area, disintegration time and wettability 
are also recommended. Finally, optimisation of processing parameters during ASD 
preparation, such as nozzle type, feed concentration, outlet temperature (for spray drying), or 
screw size, screw speed and sieve fraction (for extrusion) would further enhance control over 
critical parameters such as yield, processing time and particle size. Because an exhaustive 
trial of all possible permutations is impractical, a well-constructed design of experiment 
(DoE) approach appears the most straightforward and beneficial, given the potential for 
statistically relevant information based on fewer experimental trials. Optimisation of the 
formulation aspect of the ternary dispersions themselves using DoE has already been 
accomplished in this group and was recently reported in two separate publications (Albadarin 
et al., 2017; Davis et al., 2017). 
4. Conclusions 
The differences in downstream processing properties between amorphous solid dispersions 
prepared via hot melt extrusion or spray drying are significant. Preparation choice 
substantially impacted flow, compression and dissolution. The fundamental differences can 
be attributes to variances in particle size and morphology generated from the alternative 
preparation methods. Spray dried powders had smaller particles sizes, more complex 
morphology, were more cohesive and had poorer flow than milled extrudate. Good agreement 
was observed between various rheometric and density based parameters used to measure 
flow, such as Flow Function (FF), Relative flow function, Aeration ratio (AR), Flow rate 
index (FRI) and also the more rudimentary methods such as the Hausner ratio and Carr’s 
index. Spray dried materials produced stronger compacts during tabletability studies and had 
lower solid fractions during compactability studies. Porosity studies revealed differences in 
the mechanism of densification in extrudate and blended extrudate formulations. It was 
possible to alter the flow and compression properties of the amorphous dispersions by 
blending with specific excipients. Dissolution studies on four prototype tablets containing 
100 mg of amorphous itraconazole, revealed that drug release was faster and more complete 
from the spray dried samples and could be further influenced by selective excipient blending. 
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Figure 1: Scanning electron micrographs of (A) itraconazole x2000 (B) Soluplus® x50, (C) 
HPMCP x430, (D) physical mix x50, (E) milled extrudate < 90 µm sieve fraction x250, (F) 
milled extrudate 90 – 450 µm sieve fraction x250, (G) spray dried x250 & (H) spray dried 
x1000. 
 
Figure 2: Stability and variable flow rate data recorded on an FT4 powder rheometer for 
ASD powders of itraconazole-Soluplus®-HPMCP 30-40-30 (w/w/w), physical mix and pure 
drug. Tests 1-7 are performed at constant blade tip speed and measure stability, a stable 
powder will show an approximately flat straight line. Tests 8-11 feature a reduction in blade 
tip speed and measure the sensitivity of powder to flow rate, typically more energy is 
consumed as the blade passes at a slower speed. Measurements were recorded in triplicate. 
 Figure 3: The stability index (SI) and flow rate index (FRI) values recorded in triplicate 
for itraconazole, Soluplus®, HPMCP, physical mix, HME/BM powder and spray dried 
powder by the FT4 powder rheometer. An SI value of 1.0 ± 0.1 indicates the powder is not 
sensitive to flow stress, for example the HME/BM result. An FRI > 3.0 indicates that the 
powder is highly sensitive to flow rate and most likely cohesive, such as the value of the 
spray dried sample. 
  
 Figure 4: Aeration studies on raw materials itraconazole, Soluplus®, HPMCP and ASD 
powders prepared by hot melt extrusion then ball milling (HME & BM) or by spray drying. 
Data was recorded in triplicate on an FT4 powder rheometer. During the test, a blade is 
passed at 100 mm/s tip speed through a bed of powder while air is introduced at the base at 
progressive velocities. The extent by which the flow energy is reduced is a function of the 
physical properties of the powder (such as cohesion) and provides the aeration ratio (AR). 
 
Figure 5: Yield locus plots for itraconazole, physical mixture and ASD powders prepared 
by spray drying and by hot melt extrusion (followed by ball milling), recorded in triplicate on 
an FT4 powder rheometer. Corresponding shear parameters are recorded in Table 1. 
 Figure 6: Tabletability (a) and Compactability (b) plots of raw materials, spray dried ASD 
and milled extrudate. ITZ = itraconazole, MCC = microcrystalline cellulose, PSD = particle 
size distribution. Two sieve fractions were measured for extrudate: < 90 µm & 90 – 435 µm. 
 
Figure 7: Yield locus plots for prototype formulations, comprising spray dried (SD) powder 
with Avicel PH 200 LM microcrystalline cellulose (MCC) (Formulation 1) and Mannogem 
granular mannitol (ManG) (Formulation 2) and milled extrudate (HME/BM <90) with MCC 
(Formulation 3) and ManG (Formulation 4). For complete formulations see Table 4, for shear 
data see Table 5 and for discussion see Section 3.3.6. 
 
Figure 8: Tabletability (a) and Compactability (b) plots of spray dried (filled circles) and 
milled extrudate (open circles) & the effect of including Av200 (squares) or ManG 
(triangles). 
 
Figure 9: The change in porosity of the powder bed during compression (--- dashed line) 
of (a) extruded powders, (b) Formulation-3 and (c) Formulation-4 and the resulting Heckel 
plots, illustrating the logarithmic change in porosity (full line – ). The linear portion of the 
Heckel plot, indicating the region where the powder bed is undergoing plastic deformation, is 
indicated by a grey line of best fit. 
 Figure 10: Dissolution profiles of 500 mg prototype tablets, containing a 100 mg dose of 
amorphous itraconazole prepared by spray drying (tablets 1 & 2) or hot melt extrusion 
(tablets 3 & 4). ASDs were blended with excipients (Table 4) before compression into 
spherical disks and dissolution (n = 3) in HCl (pH 1.2), with HPLC analysis at λ = 263 nm. 
  
Please print tables in Landscape where possible 
Material Cohesion 
(C), kPa 
Flow 
Function 
(FF) 
Relative 
Flowability 
(Relp) 
UYS 
(σc), kPa 
MPS 
(σ1), kPa 
AIF (θI), o 
Itraconazole 2.55 ± 
0.17 
2.03 ± 0.03 1.80 ± 0.03 10.75 ± 
0.56 
21.85 ± 
0.82 
39.32 ± 1.34 
Physical 
mixture 
2.46 ± 
0.26 
1.98 ± 0.25 1.79 ± 0.15 11.83 ± 
2.25 
23.07 ± 
1.27 
44.09 ± 8.75 
ASD SD 1.25 ± 
0.06 
3.45 ± 0.18 2.55 ± 0.12 4.14 ± 
0.22 
14.26 ± 
0.08 
27.75 ± 0.61 
ASD 
HME/BM 
0.89 ± 
1.45 
57.01 ± 
53.62 
42.69 ± 
40.07 
2.98 ± 
4.80 
16.92 ± 
1.50 
36.39 ± 0.14 
Table 1: Results from Mohr circle analysis of shear testing performed in triplicate on 
itraconazole, physical mixture and ASD powders. Corresponding Yield locus plots are 
displayed in figure 5. 
Material ‘Conditioned
’ Bulk 
density 
(FT4), g/mL 
‘Measured
’ Bulk 
density 
(ρB), g/mL 
Tappe
d 
density 
(ρT), 
g/mL 
Hausner 
ratio (H) 
measure
d 
Hausne
r ratio 
(H) 
from 
FT4 BD 
Carr 
index (C) 
measure
d 
Carr 
index 
(C) 
from 
FT4 
BD 
Itraconazol
e 
0.51 ± 0.08 0.32 0.57 1.78 1.12 43.39 10.7
1 
Soluplus® 0.62 ± 0.02 0.61 0.69 1.13 1.11 11.59 9.91 
HPMCP 0.31 ± 0.01 0.32 0.37 1.16 1.19 13.51 15.9
7 
ASD SD 0.28 ± 0.04 0.23 0.34 1.48 1.21 32.35 17.3
6 
ASD 
HME/BM 
0.66 ± 0.01 0.59 0.80 1.36 1.21 26.25 17.3
6 
Table 2: Bulk density (BD) values obtained from FT4 (n = 3) or measured directly and 
corresponding Hausner ratios and Carr indices from both measurements (see section 3.3.5 for 
discussion). 
  
Material Flow 
Function 
(FF) 
Relative 
Flowability 
(Relp) 
Flow rate 
index 
(FRI) 
Aeration 
ratio (AR) 
Hausner 
ratio (H) 
Carr index 
(C) 
Itraconazol
e 
2.03 ± 
0.03 
(Cohesive
) 
1.80 ± 0.03 
(Extremely 
cohesive) 
1.89 ± 
0.03 
(Average 
sensitivity) 
2.30 ± 
1.05 
(Cohesive 
to 
average) 
1.78 ± 
0.17 
(Extremel
y poor 
flow) 
43.39 ± 
5.57 
(Extremel
y poor 
flow) 
Soluplus® - - 1.28 ± 
0.06 
(Flow rate 
insensitive
) 
0.48 ± 
0.05 
(Not 
sensitive, 
special 
case) 
1.13 ± 
0.01 
(Good 
flow) 
11.76 ± 
0.57 
(Good 
flow) 
HPMCP - - 1.63 ± 
0.24 
(Average 
sensitivity) 
1.52 ± 
0.15 
(Not 
sensitive, 
very 
cohesive) 
1.16 ± 
0.01 
(Good 
flow) 
13.48 ± 
0.47 
(Good 
flow) 
Physical 
mixture 
1.98 ± 
0.25 
(Very 
cohesive) 
1.79 ± 0.15 
(Extremely 
cohesive) 
1.68 ± 
0.11 
(Average 
sensitivity) 
9.76 ± 
0.58 
(Average 
sensitivity
) 
1.60 ± 
0.02 
(very 
cohesive) 
37.37 ± 
0.90 
(Very 
poor) 
Spray dried 3.45 ± 
0.18 
(Cohesive
) 
2.55 ± 0.12 
(Very 
cohesive) 
3.73 ± 
0.35 
(Highly 
sensitive) 
1.88 ± 
0.15 
(Not 
sensitive, 
very 
cohesive) 
1.47 
(Very 
cohesive) 
31.84 
(Very 
poor flow) 
Milled 
extrudate 
57.01 ± 
53.62 
(Free-
flowing) 
42.69 ± 40.07 
(Cohesionless
) 
1.40 ± 
0.02 
(Flow rate 
insensitive
) 
50.23 ± 
6.89 
(Very 
sensitive, 
low 
cohesion) 
1.20 ± 
0.01 
(Fair 
flow) 
16.87 ± 
0.29 
(Fair 
flow) 
Table 3: Comparison of material parameters related to flow. Flow function, Relative 
flowability, Flow rate index and Aeration ratio were performed in triplicate on the FT4 
powder rheometer. Hausner ratio and Carr index were measured using an accurate balance 
and graduated cylinder and are provided for comparison purposes. Interpretations are 
provided in parentheses, see section 3.3.5 for discussion.  
Numb
er 
ASD 
type 
AS
D 
mas
s 
(mg
) 
Flow / 
filler 
excipient  
Excipie
nt mass 
(mg) 
Disintegr
ant type 
Disintegr
ant mass 
(mg) 
Lubricant 
type 
Lubrica
nt mass 
(mg) 
Tablet 
1 
Spray 
dried 
333.
3 
Avicel 
PH 200 
LM 
(MCC) 
150 Ac-di-sol 11.7 Magnesi
um 
stearate 
5 
Tablet 
2 
Spray 
dried 
333.
3 
Mannoge
m 
granular 
(mannito
l) 
150 Ac-di-sol 11.7 Magnesi
um 
stearate 
5 
Tablet 
3 
HME/B
M (<90 
µm) 
333.
3 
Avicel 
PH 200 
LM 
(MCC) 
150 Ac-di-sol 11.7 Magnesi
um 
stearate 
5 
Tablet 
4 
HME/B
M (<90 
µm) 
333.
3 
Mannoge
m 
granular 
(mannito
l) 
150 Ac-di-sol 11.7 Magnesi
um 
stearate 
5 
Table 4: Prototype tablet formulations containing ternary spray dried and milled/extruded 
(HME/BM, sieve fraction < 90 µm) itraconazole ASD. Each tablet was 500 mg in size with a 
drug dose of 100 mg. The filler excipients Avicel PH 200 LM (MCC) and Mannogem 
granular (mannitol) were selected for their favourable compression, flow and low moisture 
properties. Disintegrant Ac-di-sol (croscarmellose sodium) was used at 2.3% (w/w) and 
lubricant magnesium stearate was used at 1% (w/w). 
Material Cohesion, 
kPa 
UYS, 
kPa 
MPS, 
kPa 
FF AIF, 
º 
Rel 
(p) 
Spray dried 1.59 5.22 14.44 2.77 27.2
0 
2.11 
Formulation 1 (SD & Av200) 1.13 3.47 13.10 3.78 23.7
9 
2.60 
Formulation 2 (SD & ManG) 1.84 5.66 14.26 2.52 23.9
6 
1.88 
Milled extrudate (< 90 µm) 0.66 1.97 12.97 6.59 22.0
9 
4.06 
Formulation 3 (HME/BM & 
Av200) 
0.42 1.30 13.24 10.1
5 
24.7
5 
6.40 
Formulation 4 (HME/BM & 
ManG) 
0.20 0.73 15.08 20.7
7 
33.0
5 
14.96 
Table 5: Shear data values for spray dried (SD) and milled extrudate (HME/BM, sieve 
fraction < 90 µm) ASD powders and their formulations. Av200 = Avicel 200 PH LM 
(microcrystalline cellulose); ManG = Mannogem granular (mannitol). Corresponding Yield 
locus plots are displayed in figure 7. 
 
